» Articles » PMID: 33033707

An Overview of Cancer Prevention: Chemoprevention and Immunoprevention

Overview
Journal J Cancer Prev
Specialty Oncology
Date 2020 Oct 9
PMID 33033707
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer prevention encompasses a broad spectrum of strategies designed to lower the chance of developing cancer and reduce the morbidity of established cancer. There are three levels of cancer prevention. Eliminating or mitigating cancer risk factors by adopting healthy behaviors and lifestyles, such as avoiding tobacco and alcohol use, exercising, eating a healthy diet, and applying sunscreen to protect against UV exposure, belongs to primary prevention and is the easiest and most effective way of preventing cancer for the general public. Secondary prevention includes screening to identify precancerous lesions and taking intervention measures to prevent disease progression to malignancy. Tertiary prevention refers to reducing or controlling the symptoms and morbidity of established cancer or the morbidity caused by cancer therapy. For high-risk populations, chemopreventive agents, such as selective estrogen receptor modulators (including tamoxifan and raloxifene) in breast cancer prevention and non-steroidal anti-inflammatory drugs (aspirin) in colorectal cancer prevention, and immunoprevention using human papillomavirus and hepatitis B virus vaccines in infection-related cancers have shown clear clinical benefits of reducing cancer incidences. In this review, we will summarize the current status of cancer prevention, focusing on the major agents that are clinically used for chemoprevention and immunoprevention.

Citing Articles

Hereditary Breast Cancer: Comprehensive Risk Assessment and Prevention Strategies.

Manna E, Serrano D, Cazzaniga L, Mannucci S, Zanzottera C, Fava F Genes (Basel). 2025; 16(1).

PMID: 39858629 PMC: 11764557. DOI: 10.3390/genes16010082.


Molecular Targets of Plant-Derived Bioactive Compounds in Oral Squamous Cell Carcinoma.

Mitea G, Schroder V, Iancu I, Miresan H, Iancu V, Bucur L Cancers (Basel). 2024; 16(21).

PMID: 39518052 PMC: 11545343. DOI: 10.3390/cancers16213612.


Repurposing Drugs for Cancer Prevention: Targeting Mechanisms Common to Chronic Diseases.

Choradia N, Szabo E Cancer J. 2024; 30(5):345-351.

PMID: 39312454 PMC: 11424023. DOI: 10.1097/PPO.0000000000000746.


Discovery of Natural Products for Cancer Prevention.

Blanco Carcache P, Clinton S, Kinghorn A Cancer J. 2024; 30(5):313-319.

PMID: 39312451 PMC: 11424022. DOI: 10.1097/PPO.0000000000000745.


Advancements and recent explorations of anti-cancer activity of chrysin: from molecular targets to therapeutic perspective.

Sood A, Mehrotra A, Sharma U, Aggarwal D, Singh T, Shahwan M Explor Target Antitumor Ther. 2024; 5(3):477-494.

PMID: 38966181 PMC: 11220305. DOI: 10.37349/etat.2024.00230.


References
1.
Krummel M, Allison J . CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995; 182(2):459-65. PMC: 2192127. DOI: 10.1084/jem.182.2.459. View

2.
Willis J, Reyes-Uribe L, Chang K, Lipkin S, Vilar E . Immune Activation in Mismatch Repair-Deficient Carcinogenesis: More Than Just Mutational Rate. Clin Cancer Res. 2019; 26(1):11-17. PMC: 6942620. DOI: 10.1158/1078-0432.CCR-18-0856. View

3.
Cuzick J, Sestak I, Forbes J, Dowsett M, Knox J, Cawthorn S . Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2013; 383(9922):1041-8. DOI: 10.1016/S0140-6736(13)62292-8. View

4.
Vaddepally R, Kharel P, Pandey R, Garje R, Chandra A . Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Cancers (Basel). 2020; 12(3). PMC: 7140028. DOI: 10.3390/cancers12030738. View

5.
Ni Y, Chen D . Hepatitis B vaccination in children: the Taiwan experience. Pathol Biol (Paris). 2010; 58(4):296-300. DOI: 10.1016/j.patbio.2009.11.002. View